TP53 and neoplasm: Mean tumor volume of each group (n = 7 or 8), measured twice weekly through caliper measurements, revealed a significantly elevated growth in humanized mice receiving anti-PD-1 immunotherapy unique to HCT-116 p53−/− xenografts (P = 0.04 relative to both non-humanized and humanized controls, Figure 1B blue line).